<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525691</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A03647-46</org_study_id>
    <nct_id>NCT03525691</nct_id>
  </id_info>
  <brief_title>Enhanced Lung Protective Ventilation With ECCO2R During ARDS</brief_title>
  <acronym>PROVE</acronym>
  <official_title>Enhanced Lung Protective Ventilation With Extracorporeal CO2 Removal During Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Respiratory Distress Syndrome (ARDS) is associated with a mortality rate of 30 - 45 %
      and required invasive mechanical ventilation (MV) in almost 85 % of patients[1]. During
      controlled MV, driving pressure (i.e., the difference between end-inspiratory and
      end-expiratory airway pressure) depends of both tidal volume and respiratory system
      compliance. Either excessive tidal volume or reduced lung aeration may increase the driving
      pressure. ARDS patients receiving tidal volume of 6 ml/kg predicted body weight (PBW) and
      having a day-1 driving pressure ≥ 14 cmH2O have an increased risk of death in the
      hospital[2]. Seemly, in the LUNG SAFE observational cohort, ARDS patients having a day-1
      driving pressure &lt; 11 cmH2O had the lowest risk of death in the hospital[1]. Hence, driving
      pressure acts as a major contributor of mortality in ARDS, and probably reflects excessive
      regional lung distension resulting in pro-inflammatory and fibrotic biological processes.
      Whether decreasing the driving pressure by an intervention change mortality remains an
      hypothesis; but one of means is to decrease the tidal volume from 6 to 4 ml/ kg predicted
      body weight (PBW). However, this strategy promotes hypercarbia, at constant respiratory rate,
      by decreasing the alveolar ventilation. In this setting, implementing an extracorporeal CO2
      removal (ECCO2R) therapy prevents from hypercarbia. A number of low-flow ECCO2R devices are
      now available and some of those use renal replacement therapy (RRT) platform. The
      investigators previously reported that combining a membrane oxygenator (0.65 m²) within a
      hemofiltration circuit provides efficacious low flow ECCO2R and blood purification in
      patients presenting with both ARDS and Acute Kidney injury[3].

      This study aims to investigate the efficacy of an original ECCO2R system combining a 0.67 m²
      membrane oxygenator (Lilliput 2, SORIN) inserted within a specific circuit (HP-X, BAXTER) and
      mounted on a RRT monitor (PrismafleX, BAXTER). Such a therapy only aims to provide
      decarboxylation but not blood purification and has the huge advantage to be potentially
      implemented in most ICUs without requiring a specific ECCO2R device. The study will consist
      in three periods:

        -  The first period will address the efficacy of this original ECCO2R system at tidal
           volume of 6 and 4 ml/kg PBW using an off-on-off design.

        -  The second part will investigate the effect of varying the sweep gas flow (0-2-4-6-8-10
           l/min) and the mixture of the sweep gas (Air/O2) on the CO2 removal rate.

        -  The third part will compare three ventilatory strategies applied in a crossover design:

             1. Minimal distension: Tidal volume 4 ml/kg PBW and positive end-expiratory pressure
                (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA).

             2. Maximal recruitment: 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure
                between 23 - 25 cmH2O.

             3. Standard: Tidal volume 6 ml/kg and PEEP based on the ARDSNet PEEP/FiO2 table
                (ARMA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PaCO2</measure>
    <time_frame>15 minutes after initiation of ECCO2R at tidal volume of 4 ml/kg PBW.</time_frame>
    <description>20 % decrease in PaCO2 after initiation of ECCO2R at tidal volume of 4 ml/kg PBW (as compared to 4 ml/kg without ECCO2R)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaCO2</measure>
    <time_frame>each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Arterial blood gas analyser (RAPIDPoint 500)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO2 removal rate</measure>
    <time_frame>each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using measurements from both the blood side and the gas side (two methods)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transpulmonary pressure and work of breathing</measure>
    <time_frame>each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using an oesophageal balloon catheter (NutriVent catheter) and a dedicated monitor (FluxMed, MBMed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional tidal ventilation</measure>
    <time_frame>each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using an Electrical Impedance Tomography device (BB², Swisstom)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-expiratory Lung Volume</measure>
    <time_frame>each 15 minutes up to the third hour (Part I and II of the study). In the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using the nitrogen wash-in wash-out method (Engstrom GE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines</measure>
    <time_frame>Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using Elisa custom kit (Qiagen) from plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Cytokines</measure>
    <time_frame>Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using Elisa custom kit (Qiagen) from BAL samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type III Procollagen</measure>
    <time_frame>Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using both RIA and Elisa methods from plasma and BAL samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Inflammatory and Fibrotic pathway</measure>
    <time_frame>Only in the third part, measurement at baseline and at 1 hour and at 22 hours into each arm.</time_frame>
    <description>Using mRNA custom kit RT-PCR analysis (Qiagen) from BAL samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma Free Hemoglobin</measure>
    <time_frame>every 24 hours, up to 72 hours.</time_frame>
    <description>serum samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Haptoglobin</measure>
    <time_frame>every 24 hours, up to 72 hours.</time_frame>
    <description>serum samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Lacticodéshydrogenase (LDH)</measure>
    <time_frame>every 24 hours, up to 72 hours.</time_frame>
    <description>serum samples</description>
  </other_outcome>
  <other_outcome>
    <measure>schizocytes</measure>
    <time_frame>every 24 hours, up to 72 hours.</time_frame>
    <description>serum samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Bilirubin</measure>
    <time_frame>every 24 hours, up to 72 hours.</time_frame>
    <description>serum samples</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>ARDS, Human</condition>
  <condition>Ventilator-Induced Lung Injury</condition>
  <arm_group>
    <arm_group_label>Minimal distension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maximal recruitment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low flow Extracorporeal CO2 removal</intervention_name>
    <description>Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)</description>
    <arm_group_label>Minimal distension</arm_group_label>
    <arm_group_label>Maximal recruitment</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ARDS moderate or severe (Berlin criteria)

          -  Onset &lt; 48 h

          -  Driving pressure ≥ 11 cmH2O

        Exclusion Criteria:

          -  Lack of consent or social protection

          -  Chronic respiratory failure (requiring Oxygen or NIPPV)

          -  Severe hypoxemia: PaO2/FIO2 &lt; 80 with PEEP ≥ 18 cmH2O AND FIO2= 1

          -  Acute Renal Failure requiring RRT

          -  DNR order or death expected within the next 72 hours

          -  Planned surgery or transport out-of-ICU expected within the next 72 hours

          -  Heparin allergy

          -  Contraindication to jugular vein catheterization

          -  Intracranial Hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme ALLARDET-SERVENT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Européen Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme ALLARDET-SERVENT, MD</last_name>
    <phone>+33413427155</phone>
    <email>j.allardetservent@hopital-europeen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wahiba BIDAUT</last_name>
    <email>w.bidaut@hopital-europeen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de REANIMATION, HOPITAL EUROPEEN MARSEILLE</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme ALLARDET-SERVENT, MD, MSc</last_name>
      <phone>+33413427155</phone>
      <email>j.allardetservent@hopital-europeen.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme ALLARDET-SERVENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias CASTANIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire CAMUS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.</citation>
    <PMID>26903337</PMID>
  </results_reference>
  <results_reference>
    <citation>Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, Stewart TE, Briel M, Talmor D, Mercat A, Richard JC, Carvalho CR, Brower RG. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015 Feb 19;372(8):747-55. doi: 10.1056/NEJMsa1410639.</citation>
    <PMID>25693014</PMID>
  </results_reference>
  <results_reference>
    <citation>Allardet-Servent J, Castanier M, Signouret T, Soundaravelou R, Lepidi A, Seghboyan JM. Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With Acute Respiratory Distress Syndrome and Acute Kidney Injury: The Pulmonary and Renal Support in Acute Respiratory Distress Syndrome Study. Crit Care Med. 2015 Dec;43(12):2570-81. doi: 10.1097/CCM.0000000000001296.</citation>
    <PMID>26488219</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Européen Marseille</investigator_affiliation>
    <investigator_full_name>Jerome Allardet-Servent, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Ventilator-Induced Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

